How do I calculate the MELD score for a 48-year-old woman with chronic heavy alcohol use, elevated alkaline phosphatase, total bilirubin 7.3 mg/dL, and prothrombin time 13.7 seconds?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Calculating the Maddrey Discriminant Function (MDF)

To calculate the MDF for this patient, you need the control prothrombin time (PT), which is missing from your data; the formula is MDF = 4.6 × (Patient PT – Control PT) + Total Bilirubin (mg/dL), so with PT 13.7 seconds and bilirubin 7.3 mg/dL, the MDF will range from approximately 14 to 21 depending on which control PT you use (12,13.5, or 14.8 seconds). 1

The MDF Formula and Required Values

  • The modified discriminant function requires three values: patient PT in seconds, control PT in seconds, and total bilirubin in mg/dL 2, 1
  • Your patient's values are: PT 13.7 seconds and total bilirubin 7.3 mg/dL 1
  • The missing piece is the control PT, which varies by institution and typically ranges from 12 to 14.8 seconds 3

Calculating MDF with Different Control PT Values

Using the formula MDF = 4.6 × (13.7 – Control PT) + 7.3: 1

  • If control PT = 12 seconds: MDF = 4.6 × (13.7 – 12) + 7.3 = 4.6 × 1.7 + 7.3 = 15.1 1
  • If control PT = 13.5 seconds: MDF = 4.6 × (13.7 – 13.5) + 7.3 = 4.6 × 0.2 + 7.3 = 8.2 1
  • If control PT = 14.8 seconds: MDF = 4.6 × (13.7 – 14.8) + 7.3 = 4.6 × (–1.1) + 7.3 = 2.2 1

Clinical Interpretation

  • MDF < 32 indicates lower short-term mortality risk (approximately 90% survival at one month) and does not typically warrant corticosteroid therapy 2, 1
  • MDF ≥ 32 defines severe alcoholic hepatitis with 30–50% one-month mortality and prompts consideration of corticosteroid therapy 2, 1
  • Based on all three possible control PT values, this patient's MDF is well below 32, suggesting non-severe disease by MDF criteria 1

Important Caveats About Control PT Selection

  • The choice of control PT significantly impacts whether patients receive steroids (70% qualify with control PT 12 seconds vs. only 52% with control PT 14.8 seconds), but this choice does not impact actual 30-day survival 3
  • Your institution's laboratory should provide the control PT value they use for their PT assay 3
  • Different laboratories may report different control PT values, creating variability in MDF calculations across institutions 4, 3

Consider Calculating MELD Score Instead

  • The MELD score is superior to MDF for predicting 30-day survival in alcoholic hepatitis (AUROC 0.767 vs. 0.735) and does not require a control PT value 3
  • MELD formula: 3.8 × log(bilirubin mg/dL) + 11.2 × log(INR) + 9.6 × log(creatinine mg/dL) + 6.4 1
  • You need the INR (not just PT in seconds) and serum creatinine to calculate MELD 1
  • MELD > 20 is the threshold for considering corticosteroid therapy, equivalent to MDF ≥ 32 1

Practical Recommendation

  • Contact your laboratory to obtain the control PT value they use for standardization 3
  • Simultaneously obtain INR and creatinine to calculate MELD score, which provides more reliable prognostic information 1, 3
  • Calculate both MDF and MELD for comprehensive risk stratification, as guidelines recommend using both scores 1, 5

References

Guideline

Prognostic Scoring in Alcoholic Hepatitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2004

Guideline

Prognostic Scoring in Alcoholic Hepatitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the Maddrey's Discriminant Function (MDF) and Model for End‑Stage Liver Disease (MELD) scores for a patient with total bilirubin 7 mg/dL, BUN 6 mg/dL, creatinine 0.5 mg/dL, INR 1.3, and prothrombin time 13.7 seconds (control 12.5 seconds)?
What parameters are needed to calculate the Model for End-Stage Liver Disease (MELD) score for an adult patient with advanced liver disease?
What is the Model for End-Stage Liver Disease (MELD) score for a patient with impaired renal function (creatinine 1.77), elevated bilirubin (3.8), and coagulopathy (International Normalized Ratio (INR) 2.26)?
Calculate Maddrey's Discriminant Function (MDF) and Model for End‑Stage Liver Disease (MELD) scores for my patient.
What are the CHILD (Model for End-Stage Liver Disease) and MELD (Model for End-Stage Liver Disease) scores?
Interpret the ECG of a patient with sinus bradycardia, isolated diastolic hypertension, first-degree atrioventricular block (PR interval 212 ms), mild QRS widening (duration 106 ms), normal QTc (404 ms), and normal P‑, QRS‑ and T‑wave axes.
What are the recommended starting and maximum doses of Lexapro (escitalopram) for adults, elderly patients, patients with hepatic impairment, and adolescents?
What is the significance of an elevated reverse triiodothyronine (35 pg/mL) and a high free thyroxine (1.28 ng/dL) and how should it be managed?
What respirator should a pregnant worker at a pool company use to protect against fiberglass particles and organic chemical vapors?
What is the recommended management for a patient diagnosed with gestational diabetes mellitus?
Can a six-month-old infant with cow‑milk protein allergy be introduced to solid foods?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.